Inhibition of Cdc42-intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression,...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cdc42, a Rho GTPase, is implicated in oncogenic signaling pathways crucial for lung and prostate cancers.
• The therapeutic targeting of Cdc42 is hindered by a lack of specific pharmacological agents.
• Understanding Cdc42's role is vital for developing novel cancer treatments.

Purpose of the Study:

• To identify and characterize novel pharmacological tools for modulating Cdc42 activity.
• To evaluate the anticancer potential of ZCL367, a novel Cdc42 inhibitor, in lung and prostate cancer models.
• To assess the selectivity and efficacy of ZCL367 in preclinical cancer settings.

Main Methods:

• Utilized lung and prostate cancer cell lines with diverse genetic mutations (EGFR, Ras, androgen-dependent/independent).
• Administered ZCL367 and ZCL278 to assess effects on cell cycle, proliferation, migration, and Cdc42 interactions.
• Evaluated ZCL367's potency and selectivity against Rac1 and RhoA.
• Assessed ZCL367's efficacy in a xenograft mouse model using A549 lung cancer cells.

Main Results:

• ZCL367 demonstrated potent and selective inhibition of Cdc42, suppressing cancer cell proliferation, migration, and cell cycle progression.
• ZCL367 reduced Cdc42-intersectin interactions and inhibited Cdc42-mediated filopodia formation.
• ZCL367 significantly reduced A549 tumor growth in a xenograft mouse model.
• ZCL278 exhibited partial Cdc42 agonist activity.

Conclusions:

• ZCL367 is a validated selective Cdc42 inhibitor with significant anticancer activity in preclinical lung and prostate cancer models.
• ZCL367 effectively impedes key cancer hallmarks by targeting Cdc42 signaling.
• ZCL367 represents a promising lead compound for the development of novel anticancer therapeutics targeting Cdc42.